Pieris appoints chief scientific officer

Joins German firm from Merck & Co bringing therapeutic protein drug development expertise

Laurent Audoly has joined Pieris as chief scientific officer. Audoly, most recently Biologics Research Site Lead at Merck & Co, brings both pharma and biotech experience to the German biotechnology company, particularly expertise in therapeutic protein drug development.

‘Laurent’s pharmacology expertise and drug development skills are the precise ingredients we need to maximise the value of our growing therapeutic pipeline,’ saidd Stephen Yoder, chief executive of Pieris.

‘As the company builds and expands its internal and partnered Anticalin pipeline, Laurent's contribution will be significant.’

You may also like

Regulatory

Commercialised anticalin inhaled treatments

Pieris Pharmaceuticals and AstraZeneca collaborate to develop and commercialise treatments for respiratory diseases
Ingredients

Pieris announces first cancer immunotherapy collaboration

Agreement with Roche leverages proprietary Anticalin technology platform
Research & Development

Pieris Pharmaceuticals and the University of Melbourne receive grant

To advance Anticalin-based therapeutic for inhaled delivery to treat asthmatics
Ingredients

Zydus Cadila and Pieris to collaborate on anticalin development

Collaboration combines Pieris’s drug discovery and early development capabilities with Zydus’s expertise in biologics development, regulatory affairs and biologics manufacturing
Research & Development

ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology

Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development

Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease

Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Subscribe now